Help Advance a Potential Lung Cancer Treatment
Learn more about the PADL1NK-005 clinical trial for people with non-small cell lung cancer (NSCLC)
PADL1NK-005 is exploring a study medicine that is designed to deliver a targeted treatment for non-small cell lung cancer (NSCLC)
PD-L1 is a protein found in human cells which stops the body’s immune system from attacking its own healthy cells, but it is also found in some cancers. The PADL1NK-005 clinical trial is exploring a study medicine which is designed to target PD-L1 on tumour cells and deliver an anticancer drug to eliminate them.
Your participation in this clinical trial could help advance a potential medicine for people with NSCLC. Thank you for taking the time to learn more.
Who May Participate
This trial is enrolling adults 18 years of age or older who:
-
Have been diagnosed with advanced NSCLC (Stage IIIB, IIIC or IV)
-
…which has been identified as PD-L1-positive
-
…and which has worsened despite previous treatment
There will be other requirements that the trial team will discuss with you.
Condition
Non-small cell lung cancer
Age
18+ years
Sex
Male or Female
Each clinical trial has its own guidelines for who can participate, called eligibility criteria. However, only the research trial staff can determine if you qualify to enrol in the trial.
For more information, please visit https://www.isrctn.com/.
Discover Locations for the PADL1NK-005 Clinical Trial
If you think the PADL1NK-005 clinical trial is a good fit for you and you want to take part, you can enter your zip code below to discover your nearest trial centres.
Please use the contact details for your preferred trial centre to get in touch to find out more about the PADL1NK-005 clinical trial.
When calling, please reference this trial number: C5851005
What to Expect
You will be assigned by chance to receive either the study medicine or a standard chemotherapy drug called docetaxel which is an established treatment for people with NSCLC. There is no placebo (inactive treatment) in this trial.
The study medicine is given by intravenous infusions (directly into the bloodstream via a small tube and needle) 2 times every 3 weeks. Docetaxel is given by intravenous infusions once every 3 weeks.
The total length of your participation will depend on how you and the cancer respond, any side effects you may experience, and your personal decision to remain in the clinical trial. The maximum duration is 5 years.
Length of study treatment
Depends on how the cancer responds and how well the study medicine is tolerated. The length of study treatment and follow-up may last up to 5 years.
Number of visits
About once or twice every 3 weeks.
Long-term follow up
Visits or calls every 6 weeks for the first 48 weeks, then every 12 weeks thereafter.
Frequently Asked Questions
Informed consent is one of the most important tools to help you understand how your rights, safety, and well-being will be addressed throughout the trial.
During the informed consent discussion, you will be given all details about the trial, including potential benefits and risks of taking part. You will also be given a document summarising this information, which you will sign to confirm that you would like to take part in the clinical trial.
This clinical trial is controlled, which means a comparison (control) group will be used. A comparator medicine is a “standard of care” or the established treatment that is currently used for people with a disease (such as NSCLC). In this trial, docetaxel is the comparator medicine.
Participants will receive either the study medicine or docetaxel. The study medicine is given by intravenous infusions (directly into the bloodstream via a small tube and needle) 2 times every 3 weeks. Docetaxel is given by intravenous infusions once every 3 weeks.
Participants will be assigned to a treatment group by chance (like flipping a coin) rather than by choice. This is called randomisation, and it is one way to help avoid bias in a clinical trial.
